Overview


According to FutureWise analysis the market for nanomedicine for drug delivery in 2023 is US$ 90.8 billion, and is expected to reach US$ 172.47 billion by 2031 at a CAGR of 8.35%.

Nanomedicine refers to the medical applications of Nanotechnology. Nanomedicine covers medical applications, as well as future potential applications, of nanomaterials and biosensors. The current problems in nanomedicine include understanding toxicity as well as environmental impacts of materials (materials with a structure on the order of nanometers). Nanomaterials can be enhanced with functionalities by being interconnected to biological molecules and structures. Nanomaterials are similar in size to most biological molecules and structures. This makes them useful for biomedical research in vivo as well as in vitro. The integration of nanomaterials into biology has resulted in the development of diagnostic tools, contrast agents, analytical instruments, physical therapy applications, drug delivery vehicles, and other medical devices. Nanomedicine aims to provide a wealth of clinically relevant tools and research tools in nanomedicine. The use of nanotechnology allows drugs to be delivered to specific cells by delivering them via nanoparticles. Targeted drug delivery can reduce side effects and decrease treatment costs. Targeted drug delivery also reduces the side effects of crude drugs by minimizing unwanted exposure to healthy cells. Drug delivery is focused on increasing bioavailability at specific locations in the body and for a certain period of time. This is possible with nanoengineered devices that molecularly target specific areas of the body. Also, biochemical reaction times can be much shorter. These devices are more sensitive and faster than traditional drug delivery. Nanomedicine delivers drugs to patients more efficiently than traditional drug delivery. This is due in large part to a) effective encapsulation, b) successful delivery to the target area of the body and c) successful drug release. Lipid- or polymer-based nanoparticles can be used to enhance the pharmacokinetics as well as the biodistribution of drugs. Nanoparticles can have many beneficial properties, including the ability to bypass the body's defense mechanisms. Many complex drug delivery mechanisms are being created, including the ability for drugs to pass through cell membranes and into the cell cytoplasm. Triggered responses are one-way drug molecules that can be more efficiently used. Drugs are placed inside the body and activate only when they encounter a specific signal. A drug that is difficult to dissolve will be replaced with a drug delivery system that has both hydrophilic as well as hydrophobic environments, which improves its solubility. Drug delivery systems might also be capable of preventing tissue damage by regulating drug release, reducing drug clearance rates, or lowering the volume distribution and minimizing the impact on non-target tissues. The complex reactions of the host to these nano- and microsized substances, as well as the difficulty in targeting specific organs within the body, make the biodistribution of nanoparticles still difficult. However, there is much to be done to improve and understand the limitations and potential of nanoparticle systems. 

FutureWise Market Research has instantiated a report that provides an intricate analysis of Nanomedicine for Drug Delivery Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market. 

According to the research study conducted by FutureWise research analysts, the Nanomedicine for Drug Delivery Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Abbvie Inc
  • Aquanova AG
  • BlueWillow biologics
  • Camurus AB.
  • Celgene Inc
  • Ceramisphere health pty Limited
  • Cristal Therapeutics
  • CYTIMMUNE Sciences inc
  • EnColl Corporation
  • EyePoint Pharmaceuticals

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Product Type

  • Nanoparticles
    • Metal and Metal Oxide Nanoparticles
    • Liposomes
    • Polymers and Polymer Drug Conjugates
    • Hydrogel nanoparticles
    • Dendrimers
    • Inorganic Nanoparticles
  • Nano-shells
  • Nanotubes
  • Nanodevices

By Indication

  • Oncological Diseases
  • Infectious Diseases
  • Cardiovascular Diseases
  • Orthopedic Disorders
  • Neurological Diseases
  • Urological Diseases
  • Ophthalmological Diseases
  • Immunological Diseases
  • Others

By End User

  • Hospitals
  • Specialty Clinics
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Nanomedicine for Drug Delivery Market By Product Type, By Indication, By End User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Nanomedicine for Drug Delivery Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Nanomedicine for Drug Delivery Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Nanomedicine for Drug Delivery Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Nanomedicine for Drug Delivery Market, By Product Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Nanoparticles
         1.1. Metal and Metal Oxide Nanoparticles
         1.2. Liposomes
         1.3. Polymers and Polymer Drug Conjugates
         1.4. Hydrogel nanoparticles
         1.5. Dendrimers
         1.6. Inorganic Nanoparticles
        2. Nano-shells
        3. Nanotubes
        4. Nanodevices

  • 8.   Nanomedicine for Drug Delivery Market, By Indication Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oncological Diseases
        2. Infectious Diseases
        3. Cardiovascular Diseases
        4. Orthopedic Disorders
        5. Neurological Diseases
        6. Urological Diseases
        7. Ophthalmological Diseases
        8. Immunological Diseases
        9. Others

  • 9.   Nanomedicine for Drug Delivery Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Specialty Clinics
        3. Others

  • 10.   North America Nanomedicine for Drug Delivery Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Nanomedicine for Drug Delivery Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Nanomedicine for Drug Delivery Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Nanomedicine for Drug Delivery Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Abbvie Inc
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Aquanova AG
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. BlueWillow biologics
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Camurus AB.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Celgene Inc
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Ceramisphere health pty Limited
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Cristal Therapeutics
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. CYTIMMUNE Sciences inc
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. EnColl Corporation
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. EyePoint Pharmaceuticals
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients